読み込み中
Chemomab Therapeutics Ltd. operates as a clinical-stage biotechnology firm, dedicated to identifying and advancing novel treatments for inflammatory and fibrotic conditions. Its leading experimental drug candidate, CM-101, is a humanized monoclonal antibody specifically engineered to impede the core function of soluble chemokine CCL24. This potential therapy is currently under investigation for its efficacy in managing primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). Established in 2011, the company, formerly known as Anchiano Therapeutics Ltd., adopted its current name, Chemomab Therapeutics Ltd., in March 2021 and is headquartered in Tel Aviv, Israel.
前日終値
$1.38
−$0.01 · -0.72%
日中の時刻はETです。市場データは遅延する場合があります。
Chemomab Therapeutics Ltd. operates as a clinical-stage biotechnology firm, dedicated to identifying and advancing novel treatments for inflammatory and fibrotic conditions. Its leading experimental drug candidate, CM-101, is a humanized monoclonal antibody specifically engineered to impede the core function of soluble chemokine CCL24. This potential therapy is currently under investigation for its efficacy in managing primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). Established in 2011, the company, formerly known as Anchiano Therapeutics Ltd., adopted its current name, Chemomab Therapeutics Ltd., in March 2021 and is headquartered in Tel Aviv, Israel.
日中レンジ
現在 $1.38
52週レンジ
現在 $1.38
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
33
割高
センチメント
56
まちまち
リスク
68
高リスク
モメンタム
43
中立
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Chemomab Therapeutics Ltd. operates as a clinical-stage biotechnology firm, dedicated to identifying and advancing novel treatments for inflammatory and fibrotic conditions. Its leading experimental drug candidate, CM-101, is a humanized monoclonal antibody specifically engineered to impede the core function of soluble chemokine CCL24. This potential therapy is currently under investigation for its efficacy in managing primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). Established in 2011, the company, formerly known as Anchiano Therapeutics Ltd., adopted its current name, Chemomab Therapeutics Ltd., in March 2021 and is headquartered in Tel Aviv, Israel.
日中レンジ
現在 $1.38
52週レンジ
現在 $1.38
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上原価 | — | — | 6.68万 USD | 5.78万 USD | 3.4万 USD |
| 粗利益 | — | — | −6.68万 USD | −5.78万 USD | −3.4万 USD |
| 研究開発 | 583.3万 USD | 1132.7万 USD | 1838.1万 USD | 1697.7万 USD | 630.44万 USD |
| 販売・一般管理 | 373.4万 USD | 341.2万 USD | 707.8万 USD | 1155.6万 USD | 603.72万 USD |
| 営業費用 | 956.7万 USD | 1473.9万 USD | 2545.9万 USD | 2853.3万 USD | 1234.15万 USD |
| 受取利息 | 57.2万 USD | 79.4万 USD | 123.5万 USD | 35.16万 USD | — |
| 支払利息 | — | — | — | 35.3万 USD | 11.11万 USD |
| 減価償却費と償却費 | 7万 USD | 5.3万 USD | 6.7万 USD | 5.78万 USD | 3.4万 USD |
| 営業利益 | −956.7万 USD | −1473.9万 USD | −2545.9万 USD | −2853.3万 USD | −1237.56万 USD |
| 純利益 | −899.5万 USD | −1394.5万 USD | −2422.1万 USD | −2764.6万 USD | −1248.66万 USD |
会社概要が更新されました 2026年10月11日.
AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
